MedTrace Logo

HE4 as a Relapse Biomarker in Ovarian Cancers

NCT02595281 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-12-19

No results posted yet for this study

Summary

HE4 is a more sensitive marker than CA-125 in patients with ovarian cancers. The interest of serum HE4 before surgery has been demonstrated to predict overall survival and its interest has also been shown in combination with CA-125 (ROMA algorithm) to identify high risk patients. To date, no study shows clearly the predictive potential of serum HE4 as an early relapse biomarker in ovarian cancers.

Conditions

  • Ovarian Carcinoma

Interventions

OTHER

Experimental arm

Serum samples are collected: * at each neoadjuvant chemotherapy cycle * before surgery * at each adjuvant chemotherapy cycle * at each injection of bevacizumab as maintenance therapy * stop at the progression or after 24 months post chemotherapy

Sponsors & Collaborators

  • Institut de Cancérologie de Lorraine

    lead OTHER

Principal Investigators

  • Céline Gavoille, MD · Institut de Cancérologie de Lorraine

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-01
Primary Completion
2022-07-18
Completion
2022-07-18

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02595281 on ClinicalTrials.gov